← All causality assessments
Causality: well established
Causality assessment · Causality: well established
Mosunetuzumab and Cytokine Release Syndrome: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Mosunetuzumab ↔ Cytokine Release Syndrome
n=213 co-reports · PRR 258.8 · ROR 336.9
Mosunetuzumab is a CD20-directed CD3-bispecific antibody for lymphoma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 564 co-reports (PRR 393.5) reflect near-universal occurrence.
Boxed warning: mosunetuzumab label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 393.5 with 564 co-reports |
| Consistency | met | Reproduced across BiTE/CAR T class |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for Mosunetuzumab captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.